Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMJEDI study-R1 of add-on Kampo medicine for mild to moderate COVID-19
jRCTs021200020Completed
- Sponsor
- Tsumura & Co.
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of kakkonto and shosaikotokakikyosekko in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tsumura & Co. Primary endpoints: Number of days to improve fever, Number of days to improve cough and 4 more. Started Feb 2021; status: completed.
02
Drugs
kakkontoshosaikotokakikyosekko
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs021200020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021200020.